Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Segal Trials

News headline image
Segal Trials Kicks Off CISCRP’s 8th Annual Medical Heroes Appreci-A-Thon
From Segal Trials
Via Business Wire
News headline image
Segal Trials Reinforces Leadership in Acute Schizophrenia Research Following Participation in MapLight Therapeutics’ Phase 2 ZEPHYR Study
From Segal Trials
Via Business Wire
News headline image
As Federal Fast-Tracking Accelerates Psychedelic Therapies, Segal Trials Is Positioned to Support the Next Phase of Clinical Development
From Segal Trials
Via Business Wire
News headline image
Segal Trials Participates in Research Leading to FDA Approval of Tonmya™, the First New Fibromyalgia Treatment in More Than 16 Years
From Segal Trials
Via Business Wire
News headline image
Segal Trials Contributes to Breakthrough Flu Prevention Study Led by Cidara Therapeutics
From Segal Trials
Via Business Wire
News headline image
Segal Trials Investigator Dr. Olga Lapeyra Contributes to Pivotal Migraine Study Leading to FDA Approval of Atzumi™
From Segal Trials
Via Business Wire
News headline image
Segal Trials Leads Phase 2 Schizophrenia Trial of LB-102 Toward Primary Endpoint
From Segal Trials
Via Business Wire
News headline image
Segal Trials Plays Key Role in FDA Approval of COBENFY™, A New Era in Schizophrenia Treatment
From Segal Trials
Via Business Wire
News headline image
Segal Trials to Speak on Panel at Latina Expo 2024, Hosted by CISCRP, Focusing on Diversity in Clinical Research
From Segal Trials
Via Business Wire
News headline image
Segal Trials Showcased Leadership in CNS Research and Psychedelic Studies at CNS Summit 2023
From Segal Trials
Via Business Wire
News headline image
Segal Trials Participation in Study Shows Positive Results From Phase 3 EMERGENT-2 KarXT in Schizophrenia
From Segal Trials
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.